Long-term observational study of sporadic inclusion body myositis.

We describe a long-term observational study of a large cohort of patients with sporadic inclusion body myositis and propose a sporadic inclusion body myositis weakness composite index that is easy to perform during a clinic. Data collection from two groups of patients (Paris and Oxford) was completed either during a clinic visit (52%), or by extraction from previous medical records (48%). One hundred and thirty-six patients [57% males, 61 (interquartile range 55-69) years at onset] were included. At the last visit all patients had muscle weakness (proximal British Medical Research Council scale <3/5 in 48%, distal British Medical Research Council scale <3/5 in 40%, swallowing problems in 46%). During their follow-up, 75% of patients had significant walking difficulties and 37% used a wheelchair (after a median duration from onset of 14 years). The sporadic inclusion body myositis weakness composite index, which correlated with grip strength (correlation coefficient: 0.47; P < 0.001) and Rivermead Mobility Index (correlation coefficient: 0.85; P < 0.001), decreased significantly with disease duration (correlation coefficient: -0.47; P < 0.001). The risk of death was only influenced by older age at onset of first symptoms. Seventy-one (52%) patients received immunosuppressive treatments [prednisone in 91.5%, associated (in 64.8%) with other immunomodulatory drugs (intravenous immunoglobulins, methotrexate or azathioprine) for a median duration of 40.8 months]. At the last assessment, patients who had been treated were more severely affected on disability scales (Walton P = 0.007, Rivermead Mobility Index P = 0.004) and on the sporadic inclusion body myositis weakness composite index (P = 0.04). The first stage of disease progression towards handicap for walking was more rapid among patients receiving immunosuppressive treatments (hazard ratio = 2.0, P = 0.002). This study confirms that sporadic inclusion body myositis is slowly progressive but not lethal and that immunosuppressive treatments do not ameliorate its natural course, thus confirming findings from smaller studies. Furthermore, our findings suggest that immunosuppressant drug therapy could have modestly exacerbated progression of disability. The sporadic inclusion body myositis weakness composite index might be a valuable outcome measure for future clinical trials, but requires further assessment and validation.

[1]  S. Beyenburg,et al.  Inclusion body myositis : clinical and histopathological features of 36 patients , 1993, The clinical investigator.

[2]  H. Neville,et al.  Spectrum of inclusion body myositis. , 1987, Archives of neurology.

[3]  J. Mendell,et al.  Amyloid filaments in inclusion body myositis. Novel findings provide insight into nature of filaments. , 1991, Archives of neurology.

[4]  R. Moskowitz,et al.  Steroid myopathy in connective tissue disease. , 1976, The American journal of medicine.

[5]  K J Felice,et al.  A pilot randomized trial of oxandrolone in inclusion body myositis , 2002, Neurology.

[6]  Baziel G M van Engelen,et al.  Inclusion body myositis. Clinical features and clinical course of the disease in 64 patients. , 2005, Journal of neurology.

[7]  G. Gronseth,et al.  Inclusion body myositis functional rating scale: A reliable and valid measure of disease severity , 2008, Muscle & nerve.

[8]  K J Felice,et al.  Inclusion Body Myositis in Connecticut: Observations in 35 Patients During an 8-Year Period , 2001, Medicine.

[9]  Lippincott Williams Wilkins,et al.  Randomized pilot trial of βINF1a (Avonex) in patients with inclusion body myositis , 2002, Neurology.

[10]  Allan D. Kirk,et al.  Effect of Alemtuzumab (CAMPATH 1-H) in patients with inclusion-body myositis , 2009, Brain : a journal of neurology.

[11]  M. Dalakas,et al.  Sporadic inclusion body myositis—diagnosis, pathogenesis and therapeutic strategies , 2006, Nature Clinical Practice Neurology.

[12]  Chou Sm,et al.  Inclusion body myositis: analysis of 32 cases. , 1992, The Journal of rheumatology.

[13]  J. Malley,et al.  Disease progression in sporadic inclusion body myositis: Observations in 78 patients , 2000, Neurology.

[14]  W J Litchy,et al.  Inclusion body myositis. Observations in 40 patients. , 1989, Brain : a journal of neurology.

[15]  S. Greenberg.  Inclusion body myositis: Review of recent literature , 2009, Current neurology and neuroscience reports.

[16]  Frank L Mastaglia,et al.  Inclusion body myositis: current pathogenetic concepts and diagnostic and therapeutic approaches , 2007, The Lancet Neurology.

[17]  Andrew G Engel,et al.  Correlation of muscle biopsy, clinical course, and outcome in PM and sporadic IBM , 2008, Neurology.

[18]  P H Plotz,et al.  The Treatment of Inclusion Body Myositis: A Retrospective Review and a Randomized, Prospective Trial of Immunosuppressive , 1993, Medicine.

[19]  R. Griggs,et al.  A prospective natural history study of inclusion body myositis , 2001, Neurology.

[20]  W. Engel,et al.  Inclusion Body Myositis: A Degenerative Muscle Disease Associated with Intra‐Muscle Fiber Multi‐Protein Aggregates, Proteasome Inhibition, Endoplasmic Reticulum Stress and Decreased Lysosomal Degradation , 2009, Brain pathology.

[21]  L. Deangelis,et al.  Steroid myopathy in cancer patients , 1997, Neurology.

[22]  P. Chambon,et al.  Targeted Somatic Mutagenesis in Mouse Epidermis , 2001, Hormone Research in Paediatrics.

[23]  A. Zwinderman,et al.  Comparison of weakness progression in inclusion body myositis during treatment with methotrexate or placebo , 2002, Annals of neurology.

[24]  Randomized pilot trial of high-dose βINF-1a in patients with inclusion body myositis , 2004, Neurology.

[25]  J. Dambrosia,et al.  Treatment of inclusion-body myositis with IVIg , 1997, Neurology.

[26]  S. Dimauro,et al.  Inclusion body myositis and myopathies , 1995, Annals of neurology.

[27]  P. Laforêt,et al.  Juvenile and adult-onset acid maltase deficiency in France: Genotype–phenotype correlation , 2001, Neurology.

[28]  S. Spector,et al.  A controlled study of intravenous immunoglobulin combined with prednisone in the treatment of IBM , 2001, Neurology.

[29]  M. G. Hanna,et al.  Inclusion body myositis MRC Centre for Neuromuscular Diseases, IBM workshop, London, 13 June 2008 , 2010, Neuromuscular Disorders.

[30]  Olivier Boyer,et al.  Shared blood and muscle CD8+ T-cell expansions in inclusion body myositis. , 2006, Brain : a journal of neurology.

[31]  D. Wade,et al.  The Rivermead Mobility Index: a further development of the Rivermead Motor Assessment. , 1991, International disability studies.

[32]  G. Gronseth,et al.  Inclusion body myositis: Clinical and pathological boundaries , 1996, Annals of neurology.

[33]  A. Oldfors,et al.  Anti–T-lymphocyte globulin treatment in inclusion body myositis , 2003, Neurology.

[34]  J. Vaidya,et al.  Fraction of normal remaining life span: a new method for expressing survival in cancer , 1997, BMJ.

[35]  M. Toepfer,et al.  High-dose immunoglobulin therapy in sporadic inclusion body myositis: a double-blind, placebo-controlled study , 2000, Journal of Neurology.

[36]  W. Engel,et al.  Inclusion-body myositis: muscle-fiber molecular pathology and possible pathogenic significance of its similarity to Alzheimer’s and Parkinson’s disease brains , 2008, Acta Neuropathologica.

[37]  David Hilton-Jones,et al.  International Workshop on Inclusion Body Myositis held at the Institute of Myology, Paris, on 29 May 2009 , 2010, Neuromuscular Disorders.

[38]  A. Oldfors,et al.  Inclusion body myositis: clinical, morphological, physiological and laboratory findings in 18 cases , 1994, Acta Neurologica Scandinavica.